Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 3
1968 2
1973 4
1975 2
1977 1
1978 3
1979 4
1980 2
1981 2
1982 1
1983 4
1984 3
1985 14
1986 13
1987 13
1988 17
1989 19
1990 21
1991 24
1992 20
1993 19
1994 25
1995 29
1996 35
1997 31
1998 31
1999 34
2000 27
2001 21
2002 27
2003 32
2004 25
2005 30
2006 31
2007 23
2008 29
2009 22
2010 35
2011 27
2012 35
2013 37
2014 55
2015 49
2016 44
2017 36
2018 46
2019 31
2020 25
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

997 results
Results by year
Filters applied: . Clear all
Page 1
Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial.
Al-Sulaiti FK, Nader AM, Saad MO, Shaukat A, Parakadavathu R, Elzubair A, Al-Badriyeh D, Elewa H, Awaisu A. Al-Sulaiti FK, et al. Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):639-652. doi: 10.1007/s13318-019-00551-1. Eur J Drug Metab Pharmacokinet. 2019. PMID: 30919233 Free PMC article. Clinical Trial.
OBJECTIVES: We aimed to compare clinical and pharmacokinetic outcomes between peak-trough-based and trough-only-based vancomycin TDM approaches and to determine the relationship between vancomycin AUC(24)/MIC and cure rates. ...No minimum AUC(24)/MIC breakpoint was …
OBJECTIVES: We aimed to compare clinical and pharmacokinetic outcomes between peak-trough-based and trough-only-based vancomycin TDM …
Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
Wolf J, Kalocsai K, Fortuny C, Lazar S, Bosis S, Korczowski B, Petit A, Bradford D, Croos-Dabrera R, Incera E, Melis J, van Maanen R. Wolf J, et al. Clin Infect Dis. 2020 Dec 17;71(10):2581-2588. doi: 10.1093/cid/ciz1149. Clin Infect Dis. 2020. PMID: 31773143 Free PMC article. Clinical Trial.
The proportion of participants with treatment-emergent adverse events was similar with fidaxomicin (73.5%) and vancomycin (75.0%). Of 3 deaths in the fidaxomicin arm during the study, none were CDI or treatment related. ...Systemic absorption of fidaxomicin and OP-1118 was …
The proportion of participants with treatment-emergent adverse events was similar with fidaxomicin (73.5%) and vancomycin (75.0%). Of …
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT; EXTEND Clinical Study Group. Guery B, et al. Lancet Infect Dis. 2018 Mar;18(3):296-307. doi: 10.1016/S1473-3099(17)30751-X. Epub 2017 Dec 19. Lancet Infect Dis. 2018. PMID: 29273269 Clinical Trial.
FINDINGS: Between Nov 6, 2014, and May 5, 2016, 364 patients were enrolled and randomly assigned to receive extended-pulsed fidaxomicin or vancomycin. 362 patients received at least one dose of study medication (181 in each group). 124 (70%) of 177 patients in the modified …
FINDINGS: Between Nov 6, 2014, and May 5, 2016, 364 patients were enrolled and randomly assigned to receive extended-pulsed fidaxomicin or …
Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial.
Pericàs JM, Moreno A, Almela M, García-de-la-Mària C, Marco F, Muñoz P, Peña C, de Alarcón A, Del Río A, Eworo A, Cruceta A, Paré JC, Mestres CA, Miró JM; FOSIMI Investigators. Pericàs JM, et al. Clin Microbiol Infect. 2018 Jun;24(6):673-676. doi: 10.1016/j.cmi.2018.01.010. Epub 2018 Feb 3. Clin Microbiol Infect. 2018. PMID: 29408610 Free article. Clinical Trial. No abstract available.
Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group. Louie TJ, et al. N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812. N Engl J Med. 2011. PMID: 21288078 Free article. Clinical Trial.
BACKGROUND: Clostridium difficile infection is a serious diarrheal illness associated with substantial morbidity and mortality. Patients generally have a response to oral vancomycin or metronidazole; however, the rate of recurrence is high. ...The rates of clinical cure wi …
BACKGROUND: Clostridium difficile infection is a serious diarrheal illness associated with substantial morbidity and mortality. Patients gen …
Duodenal infusion of donor feces for recurrent Clostridium difficile.
van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. van Nood E, et al. N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16. N Engl J Med. 2013. PMID: 23323867 Free article. Clinical Trial.
METHODS: We randomly assigned patients to receive one of three therapies: an initial vancomycin regimen (500 mg orally four times per day for 4 days), followed by bowel lavage and subsequent infusion of a solution of donor feces through a nasoduodenal tube; a standard v
METHODS: We randomly assigned patients to receive one of three therapies: an initial vancomycin regimen (500 mg orally four times per …
Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.
Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, Schumitzky A, Yamada W, Jones B, Minejima E. Neely MN, et al. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e02042-17. doi: 10.1128/AAC.02042-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29203493 Free PMC article. Clinical Trial.
We hypothesized that dosing vancomycin to achieve trough concentrations of >15 mg/liter overdoses many adults compared to area under the concentration-time curve (AUC)-guided dosing. ...We enrolled 252 adults who were 18 years old with 1 available vancomycin conc …
We hypothesized that dosing vancomycin to achieve trough concentrations of >15 mg/liter overdoses many adults compared to area und …
Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.
Hvas CL, Dahl Jørgensen SM, Jørgensen SP, Storgaard M, Lemming L, Hansen MM, Erikstrup C, Dahlerup JF. Hvas CL, et al. Gastroenterology. 2019 Apr;156(5):1324-1332.e3. doi: 10.1053/j.gastro.2018.12.019. Epub 2019 Jan 2. Gastroenterology. 2019. PMID: 30610862 Free article. Clinical Trial.
Patients were randomly assigned to a group that received FMT, applied by colonoscopy or nasojejunal tube, after 4-10 days of vancomycin (125 mg 4 times daily; FMTv; n = 24), 10 days of fidaxomicin (200 mg twice daily; n = 24), or 10 days of vancomycin (125 mg 4 time …
Patients were randomly assigned to a group that received FMT, applied by colonoscopy or nasojejunal tube, after 4-10 days of vancomycin
Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis.
Liu P, Capitano B, Stein A, El-Solh AA. Liu P, et al. BMC Nephrol. 2017 May 22;18(1):168. doi: 10.1186/s12882-017-0581-y. BMC Nephrol. 2017. PMID: 28532398 Free PMC article. Clinical Trial.
BACKGROUND: The primary objective of this study is to assess whether baseline renal function impacts treatment outcomes of linezolid and vancomycin (with a dose-optimized regimen) for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. ...CONCLUSIONS: In non-dial …
BACKGROUND: The primary objective of this study is to assess whether baseline renal function impacts treatment outcomes of linezolid and …
The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia.
Chavanet P. Chavanet P. Med Mal Infect. 2013 Dec;43(11-12):451-5. doi: 10.1016/j.medmal.2013.09.011. Epub 2013 Nov 13. Med Mal Infect. 2013. PMID: 24238896 Clinical Trial.
The current guidelines for the treatment of MRSA nosocomial pneumonia include vancomycin and linezolid. The authors of 2 prospective randomized trials comparing vancomycin and linezolid in nosocomial pneumonia had concluded to the non-inferiority of linezolid. ...CO …
The current guidelines for the treatment of MRSA nosocomial pneumonia include vancomycin and linezolid. The authors of 2 prospective …
997 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page